Kyverna Therapeutics
Clinical trials sponsored by Kyverna Therapeutics, explained in plain language.
-
Groundbreaking cell therapy trial aims to reset immune system in Muscle-Weakening disease
Disease control Recruiting nowThis study is testing an experimental cell therapy called KYV-101 for adults with generalized myasthenia gravis, a disease that causes severe muscle weakness. The therapy, known as CAR T, is designed to reset the immune system by removing harmful B cells that attack the body. Res…
Phase: PHASE2, PHASE3 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
15-Year watch begins for patients who received experimental autoimmune therapy
Knowledge-focused Recruiting nowThis study is tracking the long-term safety and effects of an experimental cell therapy called KYV-101 in people who have already received it. Researchers will follow 70 participants for up to 15 years to check for any delayed side effects and see how long the treatment's effects…
Sponsor: Kyverna Therapeutics • Aim: Knowledge-focused
Last updated Mar 20, 2026 14:47 UTC